|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 未行淋巴清扫的早期卵巢癌81例生存率的回顾性分析显示文摘目的:探讨对于因各种原因而未行淋巴清扫的早期卵巢癌患者,若不行二次分期手术,而是给予辅助化疗,其生存率是否会受影响。方法:收集1992年1月—2002年12月所有在香港玛丽医院妇产科就治的、因各种原因未接受淋巴清扫的、肉眼直视观察肿瘤局限于卵巢的Ⅰ期卵巢癌病例进行回顾性分析。结果:有81例患者被纳为研究对象,其中ⅠA期23例,ⅠB期1例,ⅠC期57例。年龄范围21~81岁,平均年龄47岁。随访时间50~179个月,平均随访时间为110个月。其中有64例(79.0%)患者接受了辅助化疗。总的5年生存率和4年无瘤生存率分别为91.4%和85.2%,与文献报道的行淋巴清扫后的结果相近。结论:对于未行淋巴清扫而病变局限于卵巢的Ⅰ期卵巢癌患者,若辅以适当的化疗,可以使她们获得与行淋巴清扫患者同样的生存率。 | 陈金虹 Karen KL CHAN Kar Fai TAM Hextan YS NGAN | 2008 | 肿瘤2008，28，12： | 3 |
| 2 | A longitudinal study on quality of life after gynecologic cancer treatment 显示文摘 | YM-Chan Hextan YS Ngan Billy YG Li | 2001 | Gynecologic oncology2001，83，1： | 1 |
| 3 | The use of music to reduce anxiety for patients undergoing colposcopy: a randomized trial显示文摘 | Y.M Chan Peter W.H Lee T.Y Ng Hextan Y.S Ngan L.C Wong | 2003 | Gynecologic Oncology2003，，1： | 1 |
| 4 | Genetic abnormalities and HPV status in cervical and vulvar squamous cell carcinomas显示文摘 | Fung Yu Huang Yvonne K.Y. Kwok Elizabeth T. Lau Mary H.Y. Tang Tong Yow Ng Hextan Y.S. Ngan | 2005 | Cancer Genetics and Cytogenetics2005，，1： | 1 |
| 5 | Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges显示文摘开发和有效 anticancer 治疗的战略申请结果是管理人的癌症的最批评的途径之一。不过,药抵抗是为这些疾病的临床的管理的主要障碍特别卵巢的癌症。在过去的年里,实质的研究与探索其他的治疗学的途径提高副作用引起了以便在全面幸存生产重要优点并且改进生活的病人质量的当前的化学疗法的政体和还原剂的功效的目的被执行了。由激活代理人的激活安培的蛋白质 kinase (AMPK ) 的申请指向癌症房间新陈代谢被相信是最嘴巧的尝试之一。象 5-aminoimidazole-4-carboxamide 1--d-ribofuranoside, A23187, metformin,和痛苦的甜瓜那样的 AMPK 使活跃之物提取不仅阻止癌症前进和转移而且也装作为补充被使用在象卵巢的癌症那样的人的癌症提高基于 cisplatin 的化疗的功效。因为与在临床的试用被利用了的很药品的 AMPK 使活跃之物的经常的有毒的副作用一起的不受欢迎的结果,然而,当前的研究的注意从 nutraceuticals 或传统的药针对了可替代的试剂的鉴定。然而,在 anticancer 的许多 nutraceuticals 的内在的分子的机制仍然保持阴暗。因此,更好功能的描述和自然 AMPK 使活跃之物的规章的机制理解将在打开一个区域干涉帮助药品的开发卵巢的癌症和其它人癌症。 | Mingo M.H. Yung Hextan Y.S. Ngan David W. Chan | 2016 | Acta Biochimica et Biophysica Sinica2016，48，4： | 1 |
| 6 | Proliferation to apoptosis ratio as a prognostic marker in adenocarcinoma of uterine cervix显示文摘 | Tsin-Wah Leung Wei-Cheng Xue Annie N.Y Cheung Ui-Soon Khoo Hextan Y.S Ngan | 2004 | Gynecologic Oncology2004，，3： | 1 |
| 7 | Human PaPillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine:immunogenicity and safety in healthy Chinese women from Hong Kong显示文摘 | Hextan YS Ngan Annie NY Cheung KF Tam | 2010 | Hong Kong Med2010，16，3： | 1 |
| 8 | Epidemiology of Human Papillomavirus Infection and Cervical Cancer and Future Perspectives in Hong Kong, Singapore and Taiwan显示文摘 | Sun Kuie Tay Hextan Y.S. Ngan Tang-Yuan Chu Annie N.Y. Cheung Eng Hseon Tay | 2008 | Vaccine2008，，： | 1 |
| 9 | Human PaPillomavirus-16 /18 AS04-adjuvanted cervi- cal cancervaccine: immunogenicity and safety in healthy Chinese women from Hong Kong显示文摘 | Hextan Y S Ngan Annie N Y Cheung Tam K F | 2010 | Hong Kong Med2010，16，3： | 1 |
| 10 | A longitudeinal study on quality of life after gynecologic cancer treatment显示文摘 | YM Chan Hextan YS Ngan Billy YG Li | 2001 | Gynecologic Oncology2001，83，1： | 1 |
| 11 | The increase of mitochondrial DNA content in endometrial adenocarcinoma cells: A quantitative study using laser-captured microdissected tissues显示文摘 | Yue Wang Vincent W.S. Liu Wei-Cheng Xue Percy C.K. Tsang Annie N.Y. Cheung Hextan Y.S. Ngan | 2005 | Gynecologic Oncology2005，，1： | 1 |
| 12 | The increase of mitochondrial DNA content in endometrial adenocarcinoma cells: A quantitative study using laser-captured microdissected tissues显示文摘 | Yue Wang Vincent W.S. Liu Wei-Cheng Xue Percy C.K. Tsang Annie N.Y. Cheung Hextan Y.S. Ngan | 2005 | Gynecologic Oncology2005，，1： | 1 |
| 13 | Early detection of persistent trophoblastic tumour by serum human chorionic gonadotrophin monitoring after molar pregnancy显示文摘ObjectiveTostudytheoutcomeofamulticentredpostmolarpregnancyserumhumanchorionicgonadotrophin(hCG)surveilanceprogramme.Method... | Hextan Yuen Sheung Ngan and Ling Chiu Wong Department of Obstetrics and Gynaecology, University of Hong Kong, Queen Mary Hospital, Hong Kong, China (Ngan HYS and Wong LC) | 1999 | Chinese Medical Journal1999，，3： | 0 |
| 14 | A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy:a case report显示文摘We report our experience in the management of a relapsed ovarian cancer patient with somatic RAD51C mutation,treated with olaparib monotherapy.The patient was diagnosed with stage 4 high-grade serous ovarian carcinoma and was treated with neoadjuvant chemotherapy,cytoreductive surgery,and postoperative chemotherapy.After a second cancer recurrence,she underwent FoundationOne CDx testing following disease progression on multiple lines of chemotherapy.Based on the FoundationOne CDx results,olaparib monotherapy was started.After 13 months of therapy,all lesions responded to the treatment,and she achieved complete response as demonstrated by normalization of the levels of CA125 and positron emission tomography-computed tomography(PET-CT).We plan to continue olaparib monotherapy until disease progression. | Siew-Fei Ngu Hextan Y.S.Ngan Karen K.L.Chan | 2022 | Cancer Drug Resistance2022，5，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员